Punctuality is very important in the Dutch business culture. People have busy and full schedules, and appreciate timeliness. Read on to learn more about the Netherlands.
The author considers her dilemma of deciding whether or not step in and help another person with professional and/or personal struggles, and how that decision has shaped her growth as a leader.
This excerpt is from 2013 U.S. Sentencing Commission Guidelines Manual, Chapter 8, Part B, Remedying Harm from Criminal Conduct
The author considers Keith Chen’s proposal: The language you speak affects how much you save.
This author tackles the question: Are corporations taking on excessive enterprise risks by failing to make prudent investments in their compliance and ethics functions?
Many jurisdictions in the Asia-Pacific region have enacted, or are in the process of enacting, comprehensive data privacy legislation. Learn how this may impact your business.
For a corporation facing the cross-border discovery challenge of collecting information from its foreign offices, there is no easy solution. This article offers some tips: Technology- assisted review and digital rights management technology can facilitate negotiations with local data protection authorities.
Clive Anderson oversees Manulife’s legal and compliance functions in seven Southeast Asian countries, including Singapore, Cambodia, Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Read this article to learn his take on Manulife’s Pan-Asia growth strategy.
Contract manufacturing involves negotiation between two parties: the manufacturer and the brand name owner. For commercial purposes, the arrangement works well. Each party is able to focus on their core competencies. However, when the lawyers sit down to hammer out the contracts, problems often arise. Three strategies can resolve contractual issues: the one-to-one contracting model, agreements in tandem, or a Joinder, which brings the contract manufacturer under the terms of the Master Agreement.
On the transparency front, it was a busy summer for the European Federation of Pharmaceutical Industries and Associations (EFPIA). In the wake of recent ‘Sunshine’ legislation in France and other EU countries, and pending transparency trials before the Court of Justice of the European Union (CJEU), EFPIA adopted no less than two brand new transparency documents: a Disclosure – ‘Sunshine’ – Code and joint Principles for Responsible Clinical Trial Sharing. It also significantly strengthened the advertisement commitments in its existing Code on Interactions with HCPs.